Prescription Drug Supply Chain Pricing Transparency Act

Bill 118 s 2198, also known as the Prescription Drug Supply Chain Pricing Transparency Act, aims to increase transparency in the pricing of prescription drugs within the supply chain. The bill was introduced in the US Congress with the goal of addressing concerns about rising drug prices and the lack of transparency in how these prices are determined.

The key provisions of the bill include requiring drug manufacturers to provide information on the pricing of prescription drugs, including the costs of production, research and development, and marketing. This information would be made publicly available to help consumers and policymakers better understand the factors that contribute to the high cost of prescription drugs.

Additionally, the bill would require pharmacy benefit managers (PBMs) to disclose any rebates or discounts they receive from drug manufacturers, as well as any fees or payments they receive from pharmacies. This transparency is intended to ensure that PBMs are not engaging in practices that could drive up drug prices for consumers. Overall, the Prescription Drug Supply Chain Pricing Transparency Act seeks to shed light on the complex pricing dynamics within the prescription drug supply chain and empower consumers to make more informed decisions about their healthcare. The bill is currently under consideration in Congress and has garnered bipartisan support for its efforts to increase transparency and accountability in the pharmaceutical industry.